- Acushnet: Truist Securities adjusts price target to $48 from $56, maintains hold rating
- BAE Systems: DZ Bank downgrades to hold from buy. PT up 2.2% to 740 pence.
- Ball: BMO Capital Markets upgrades to outperform from market perform. PT up 19% to $105.
- Bristol-Myers Squibb: UBS adjusts price target to $70 from $61, maintains neutral rating
- Citigroup: Atlantic Equities downgrades to neutral from overweight. PT up 18% to $70.
- Foot Locker: UBS adjusts price target to $32 from $48, maintains neutral rating.
- Hikma: Morgan Stanley upgrades from Overweight to equal weight with a target of GBp 2300.
- Intel: Morgan Stanley downgrades to underweight from equal-weight. PT down 3.8% to $47.
- iQIYI: JPMorgan upgrades to overweight from neutral, raises price target to $8 from $5
- Neurocrine Bio: Piper Sandler downgrades to neutral from overweight. PT up 2.3% to $94.
- Polymetal: Berenberg remains Buy with a target reduced from GBp 1000 to GBp 500.
- Ross Stores: Morgan Stanley adjusts the price target to $137 from $140, maintains overweight rating
- Salesforce.com: Canaccord Genuity adjusts the price target to $260 from $315, maintains buy rating
- S&P Global: Morgan Stanley raises price target to $480 from $470, maintains overweight rating
- Target: Raymond James adjusts pt to $275 from $290, maintains strong buy rating
- Teradyne: Morgan Stanley downgrades to equal-weight from overweight. PT up 13% to $132.
- ZAI Lab Limited: SVB Leerink adjusts the price target to $102 from $194, maintains outperform rating